Korea FilingsFull brief — $39

HANALL BIOPHARMA CO.,LTD

한올바이오파마(주) · KOSPI: 009420 · Pharmaceuticals and medicinal chemicals

Key facts

Korean name
한올바이오파마(주)
Market / ticker
KOSPI · 009420
Industry
Pharmaceuticals and medicinal chemicals
Established
1973-11-20
Fiscal year ends
December
Website
www.hanall.co.kr
DART corp code
00162586
Latest revenue
₩155.2B (FY2025)

Items worth checking

low
Filing on a change in the CEO line-up — filed 2026-03-26.

Financial summary

KRWFY2023FY2024FY2025
Revenue₩134.9B₩138.9B₩155.2B
Operating income₩2.2B₩230M−₩916M
Net income₩3.5B−₩1.8B−₩5.6B
Total assets₩239.7B₩212.9B₩225.2B
Total liabilities₩53.5B₩44.5B₩63.5B
Total equity₩186.2B₩168.4B₩161.7B
Share capital₩26.1B₩26.1B₩26.1B

Consolidated statements · FY2025 operating margin -0.6% · liabilities to equity 39% · Annual report FY2025 (Korean original)

Auditor opinions

PeriodAuditorOpinion
Term 53 (current)한영회계법인Unqualified
Term 52 (prior)삼정회계법인Unqualified
Term 51 (two years prior)삼정회계법인Unqualified

Largest shareholder history

No change history reported in the latest annual report.

Recent filings

DateFilingOriginal
2026-08-14Half-year report (2026.06)DART
2026-07-31Investor relations event (notice)DART
2026-07-29Preliminary consolidated operating results (fair disclosure)DART
2026-07-22Amended: Material management matterDART
2026-07-22Material management matterDART
2026-07-02Officer / major shareholder ownership reportDART
2026-07-01Large shareholding (5%+) reportDART
2026-06-30Sustainability report (voluntary)DART
2026-06-01Corporate governance reportDART
2026-05-28Investor relations event (notice)DART
2026-05-20Amended: Material management matterDART
2026-05-15Quarterly report (2026.03)DART
2026-05-06Treasury share disposal results reportDART
2026-05-06Officer / major shareholder ownership reportDART
2026-05-06Officer / major shareholder ownership reportDART
2026-05-06Officer / major shareholder ownership reportDART
2026-05-06Change in shareholdings of largest shareholderDART
2026-04-29Material event report — Treasury share disposal decisionDART
2026-04-29Preliminary consolidated operating results (fair disclosure)DART
2026-04-13Investor relations event (notice)DART

Showing the 20 most recent of 50 filings. The full brief lists all of them.

Full brief on HANALL BIOPHARMA CO.,LTD — $39 Get the full brief

For business customers. EU companies: enter your VAT number at checkout and no VAT is charged (reverse charge).

Other Korean companies in Pharmaceuticals and medicinal chemicals

Data generated 2026-09-16 from OpenDART.

This page summarizes public filings from DART, the official electronic disclosure system of Korea. It is not investment, credit or legal advice. Figures are shown in the currency the company reports in. Titles and labels are machine-translated and may contain errors — always check the linked original filing. Source: OpenDART, Financial Supervisory Service, Korea.